menu
    • menu
    [{"orgOrder":0,"company":"Origo Biopharma","sponsor":"AgomAb Therapeutics N.V","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agomab Therapeutics to Acquire Origo Biopharma","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"ORG-129","moa":"TGF-beta","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Origo Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Origo Biopharma \/ Agomab","highestDevelopmentStatusID":"6","companyTruncated":"Origo Biopharma \/ Agomab"}]

    Find Clinical Drug Pipeline Developments & Deals by Origo Biopharma

    Menu

    Origo Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Origo Biopharma

                            Spain arrow
                            FNCE 2024
                            Not Confirmed

                            Origo Biopharma

                            Spain arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORG-129

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : AgomAb Therapeutics N.V

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Agomab Therapeutics to Acquire Origo Biopharma

                            Details : The combined organization will focus on translating growth factor signaling pathways into innovative therapies including lead program, ORG-129, a gastrointestinal tract restricted ALK-5 inhibitor currently in a Phase 1 clinical trial.

                            Brand Name : ORG-129

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 28, 2021

                            Lead Product(s) : ORG-129

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : AgomAb Therapeutics N.V

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth